Open access
Aug 2026
Targeting of the oncogenic fusion EWSR1-FLI1 in Ewing Sarcoma by CRISPR/dCas9 silencers.
An effective non-viral platform for in vivo delivery of dCas9-KRAB/RNPs, which could be adapted for the repression of any oncogene is characterized.
Shahama Taifour, Chee-Wai Wong, Christopher P. Wallis et al.
· Molecular Therapy · 0 citations